[A17-20] Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2017
Project no.:
A17-20
Commission:
Commission awarded on 02.05.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Advanced NSCLC (lung cancer) with T790M mutation after pretreatment with EGFR-TKI
Hint for non-quantifiable, at least considerable added benefit versus cisplatin + pemetrexed
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-45 | Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-47 | Osimertinib (lung cancer) - Addendum to Commission A17-20 | Commission completed |
| A16-14 | Osimertinib - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-77 | Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-72 | Osimertinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-86 | Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-10-19 A G-BA decision was published.